A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies.
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2013
At a glance
- Drugs Capecitabine (Primary) ; Imatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Oct 2007 Status change from recruiting to completed.
- 25 Dec 2005 New trial record.